Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer - Wikidata - awgldk - TriplyDB

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

http://www.wikidata.org/entity/Q34721664

about

Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer Classic tumor markers in gastric cancer. Current standards and limitations May Circulating microRNAs be Gastric Cancer Diagnostic Biomarkers?Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications Bioinformatic Interrogation of 5p-arm and 3p-arm Specific miRNA Expression Using TCGA Datasets Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer MicroRNA-146a affects the chemotherapeutic sensitivity and prognosis of advanced gastric cancer through the regulation of LIN52 Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages.Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update.MicroRNAs as potential biomarkers for gastric cancer.Chronic bronchitis with fungal infection presenting with marked elevation of serum carbohydrate antigen 19-9: a case report.Serum levels of preoperative α-fetoprotein and CA19-9 predict survival of hepatic carcinoma patients after liver transplantation.Preoperative CA 125 is significant indicator of curative resection in gastric cancer patients.Hemolysis-free plasma miR-214 as novel biomarker of gastric cancer and is correlated with distant metastasis Clinical significance of serum thymus and activation-regulated chemokine in gastric cancer: potential as a serum biomarker.Identification of the long non-coding RNA H19 in plasma as a novel biomarker for diagnosis of gastric cancer.Clinicopathological features and prognosis of gastric cancer in young patients Diagnostic significance of miR-106a in gastric cancer.Differences and correlation of serum CEA, CA19-9 and CA72-4 in gastric cancer.Predictive Role of Serum Tumor Markers in Diagnosis of Pulmonary Tuberculosis.Potential role of microRNA-126 in the diagnosis of cancers: A systematic review and meta-analysis Prognostic significance of preoperative serum CA125, CA19-9 and CEA in gastric carcinoma.Advances in molecular biomarkers for gastric cancer: miRNAs as emerging novel cancer markers.Relationship between Serum Level of Lymphatic Vessel Endothelial Hyaluronan Receptor-1 and Prognosis in Patients with Lung Cancer.Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer.Tumour-associated antigens and their anti-cancer applications.Pulmonary sequestration presenting with left upper abdominal bloating and marked elevation of serum carbohydrate antigen 19-9: A case report Three-dimensional combined biomarkers assay could improve diagnostic accuracy for gastric cancer.Combination of miRNA and RNA functions as potential biomarkers for gastric cancer.Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer.Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva.Expression of the cytoskeleton regulatory protein Mena in human gastric carcinoma and its prognostic significance.The role of TFPI2 hypermethylation in the detection of gastric and colorectal cancer.High serum carbohydrate antigen 125 concentration can predict serous effusion but not gastrointestinal malignancy in male patients.Potential Role of MicroRNA-375 as Biomarker in Human Cancers Detection: A Meta-Analysis.Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer.The prognostic role of MAC30 in advanced gastric cancer patients receiving platinum-based chemotherapy.A novel classifier based on three preoperative tumor markers predicting the cancer-specific survival of gastric cancer (CEA, CA19-9 and CA72-4).Responsive photonic barcodes for sensitive multiplex bioassay.

P2860

Q26746010-4A06C46E-50E0-4CF9-9B9F-07CDC3F1B0B5 Q26777296-08537F07-7887-4B95-9D0F-2410A15D5BC3 Q26780339-40D97D12-E9B3-4106-8E63-3E5A812332D7 Q27012898-A9A84C3F-32C7-4A62-A70A-07979CDBB72D Q30488342-44D69777-4653-4AF8-B43A-D027DC0625E4 Q31112933-8AF37C50-F153-42CC-8B43-25739CFE41B5 Q33591586-F7A6EDEC-5D72-4E24-B5FB-C7CF25C8A19E Q33598225-A769199D-5610-4FB8-AFF7-328F63B40A89 Q33640472-109263D2-CC93-431C-A471-C37B362F9B1D Q33805874-8C8F9004-FCAB-4762-9656-001A4F7457CB Q34168445-E8DDC403-00FD-4939-A085-D667BC197956 Q34371789-1A618A77-58EB-4201-9975-3607406EF030 Q34660116-081337D8-7491-458B-A0FF-6C470E5F3443 Q35012088-A20D39B9-EBC4-4A11-9014-9BFEE7279FB9 Q35402769-F7B09F7E-6A52-4558-A1FA-CA1BFAC0DE33 Q35713297-E18E9FFA-8420-41E1-B476-5DE0B040AA1B Q35764908-D66B8A83-F525-4C35-8085-130EAD920090 Q36078244-4A05E645-7D28-4672-BD72-FDB60921797A Q36375328-BEE96C91-1C57-4E8E-AD5C-35B7FFA4A896 Q36640236-2C8686DF-B731-4F02-AEC0-DD0AE7D83B1C Q36954424-8F7B08A4-44F0-4C38-9839-F5891EF222B6 Q37226272-BD57C065-A7D8-4A34-BCD0-BA28ABF62567 Q37376572-CFFCA8EC-217F-438F-B1BF-5BB9F2466EDF Q37537123-6F1769D7-00E0-46A7-BC12-31D625115FE6 Q37657329-0EAC4E5D-50C5-4B19-BF28-CCB9D2340D19 Q37697593-09962F5A-A46F-4DA9-ABCC-B66A628A945E Q38725552-5EEA38B6-09FF-4500-86BE-EB248268C93D Q38932816-BC30E1B3-9601-4951-AB91-9D6FD6A8D2CF Q40039986-41483CC5-2B3A-412D-AFD7-748AB230AB85 Q40743782-448BFA7B-0728-4C8F-BE13-D68566552E68 Q42378441-90C381E5-1EE1-42FE-89DC-018C9DACB50B Q45956385-7FFE8DE8-E528-4370-A07D-68647BFE13CA Q46053682-CA13B202-025F-4B19-B11F-7B08E5017356 Q46123774-C8BC5827-07FE-4617-9819-9A62E0991B95 Q46673252-AD0C5D41-BEB3-44DF-81B0-C567F433A696 Q47109479-99338F84-A30B-4301-B8BB-2E438480A390 Q47124055-AA2B15E4-1ABD-42BF-806E-7BEE26142438 Q47755443-36738791-2918-41A9-9FD2-E5D6DABB92C5 Q50052974-C0C86E61-4E49-4A0D-B216-65776CBFDE08 Q50120382-2EB28CC6-331A-4067-88FC-6115C836DF3D

P2860

Combined use of AFP, CEA, CA125 and CAl9-9 improves the sensitivity for the diagnosis of gastric cancer

http://www.wikidata.org/entity/Q34721664

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@ast

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@en

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@nl

type

label

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@ast

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@en

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@nl

prefLabel

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@ast

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@en

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@nl

P1433

Q34721664-994C9467-F508-48C1-AA8F-1EBB89E48FE3

P1476

Q34721664-98EBA2C2-2E86-4BD0-BDE8-505927329AE3

P2093

Q34721664-0C973540-5E5E-4945-BE6C-DBB74EB49EC9

Q34721664-452338D8-05DC-47EE-8E09-761094650B88

Q34721664-48F8CC4A-B1F8-4401-96B1-598830AB54F8

Q34721664-49A96747-9977-456F-BB23-B92C451FF791

Q34721664-7853A2B7-B081-4197-AC8D-95793FD243AD

Q34721664-B93B8A41-986F-404F-87FF-A53D8B26B745

P2860

Q34721664-35A3E13D-0B0C-4A5E-B8AF-0EC3B900537B

Q34721664-72CD44DB-4675-45F6-B8F1-CB765E6376DA

Q34721664-8A4E320B-E90C-4A81-BCF2-E69C24A20DAD

Q34721664-B30E829A-73B0-4AC6-9817-158AC59BAE18

Q34721664-B9DC46BD-7F67-4ECB-9FA3-6FA85B5DDB39

Q34721664-E576C168-FCA9-47AF-88DC-3E0ADA11A1F8

Q34721664-EC716193-B404-4172-A010-B8E51425DAD6

P2888

Q34721664-D224D0BA-A690-4477-A043-09590B637829

P304

Q34721664-93A79319-128D-4CC4-A069-4A975915190B

P31

Q34721664-457B219A-A460-4712-A5C9-B5A98775A8FC

P356

Q34721664-7478DD87-F5A2-4B80-A77E-E63A65BCC257

P478

Q34721664-E311598A-F736-43AD-8C77-95E4E5914456

P577

Q34721664-4B11EE88-D80E-4E0E-B37E-0B58F118DDB3

P6179

Q34721664-92FE77E6-D79C-4FD0-AFC9-9F7C177BF73F

P698

Q34721664-FF12DC0E-FC63-44F0-B1BA-F0565C8D8261

P932

Q34721664-B2A1E4EE-7E16-466E-BC86-38A3088BFCDF

P356

1471-230X-13-87

P1433

BMC Gastroenterology

P1476

Combined use of AFP, CEA, CA12 ...... he diagnosis of gastric cancer

@en

P2093

Chao-Zhu He

http://www.w3.org/2001/XMLSchema#string

Kun-He Zhang

http://www.w3.org/2001/XMLSchema#string

Nong-Hua Lv

http://www.w3.org/2001/XMLSchema#string

Qing Li

http://www.w3.org/2001/XMLSchema#string

Xiao-Hua Liu

http://www.w3.org/2001/XMLSchema#string

Yan Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.

Serological assessment of gastric mucosal atrophy in gastric cancer.

The use of a combination of Ki-67, Galectin-3, and PTTG can distinguish the benign and malignant thyroid tumor.

Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer

Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Tumour marker CA 125 in patients with digestive tract malignancies.

The use of tumor markers as predictors of prognosis in gastric cancer.

P2888

1471-230x-13-87

P304

87

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-230X-13-87

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1039858407

http://www.w3.org/2001/XMLSchema#string

P698

23672279

http://www.w3.org/2001/XMLSchema#string

P932

3655895

http://www.w3.org/2001/XMLSchema#string